multiple myeloma
NICE publishes new myeloma guidance
February 10, 2016Medical Communications, Research and Development Farydak, Novartis, multiple myeloma
NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
FDA approves new Kyprolis combo for multiple myeloma
January 22, 2016Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Takeda’s Ninlaro extends myeloma survival in trial
December 7, 2015Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma
Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
MSD’s Keytruda shows promise in multiple myeloma
December 7, 2015Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab
MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
FDA approves BMS and AbbVie’s Empliciti for multiple myeloma
December 1, 2015Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma
The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …
Clinigen launches UK managed access program for Takeda’s ixazomib
November 30, 2015Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology
Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …
Challenges in oncology R&D
November 18, 2015Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
Amgen’s Kyprolis gets accelerated FDA review for expanded labelling
September 21, 2015Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma
The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …
NICE rejects Farydak for multiple myeloma
September 16, 2015Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat
NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …
Janssen submits EMA application for myeloma drug
September 14, 2015Sales and Marketing Janssen, daratumumab, multiple myeloma
Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …
Novartis blood cancer drug Farydak receives EU approval
September 4, 2015Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat
The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
Takeda gets European MAA approval for ixazomib
August 21, 2015Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma
Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …
Latest content
FibroFind appoints Lee Borthwick as CEO
